Impact of polymers on the precipitation behavior of highly supersaturated aqueous danazol solutions

Molecular Pharmaceutics

Volumn 11, Issue 9, 2014, Pages 3027-3038

  Jackson, Matthew J ^a   Toth, Scott J ^b   Kestur, Umesh S ^c   Huang, Jun ^c   Qian, Feng ^d   Hussain, Munir A ^c   Simpson, Garth J ^b   Taylor, Lynne S ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Tsinghua University   (China)

Author keywords

amorphous solubility; crystallization inhibition; polymers; supersaturation

Indexed keywords

DANAZOL; POLYMER; SOLUTION AND SOLUBILITY; WATER;

CHEMICAL PHENOMENA; CHEMISTRY; CRYSTALLIZATION; PARTICLE SIZE; PRECIPITATION; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY;

CHEMICAL PRECIPITATION; CRYSTALLIZATION; DANAZOL; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PARTICLE SIZE; POLYMERS; SOLUBILITY; SOLUTIONS; WATER;

EID: 84906898072     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500201s     Document Type: Article

References (52)

1. Dahan, A.; Hoffman, A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs J. Controlled Release 2008, 129 (1) 1-10
2. Miller, J. M.; Beig, A.; Carr, R. A.; Spence, J. K.; Dahan, A. A Win-Win Solution in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid Dispersions Increases Apparent Solubility without Sacrifice of Intestinal Membrane Mol. Pharmaceutics 2012, 9, 2009-2016
3. Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubililty Advantage of Amorphous Pharmaceuticals: II. Application of Quantitative Thermodynamic Relationships for Prediction of Solubility Enhancement in Structurally Diverse Insoluble Pharmaceuticals Pharm. Res. 2012, 27, 2704-2714
4. Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility Advantage of Amorphous Pharmaceuticals, Part 3: Is Maximum Solubility Adavntage Experimentally Attainable and Sustainable? J. Pharm. Sci. 2011, 100 (10) 4349-4356
5. Hancock, B. C.; Parks, M. What is the True Solubility Advantage for Amorphous Pharmaceuticals Pharm. Res. 2000, 14 (4) 397-404
6. Hancock, B. C.; Zografi, G. Characteristics and Significane of the Amorphous State in Pharmaceutical Systems J. Pharm. Sci. 1997, 86 (1) 1-12
7. Marsac, P. J.; Konno, H.; Taylor, L. S. A comparison of the physical stability of amorphous felodipine and nifedipine systems Pharm. Res. 2006, 23, 2306-2316
8. Alonzo, D. E.; Zhang, G.; Zhou, D.; Gao, Y.; Taylor, L. S. Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution Pharm. Res. 2010, 27 (4) 608-618
9. Alonzo, D. E.; Gao, Y.; Zhou, D.; Mo, H.; Zhang, G.; Taylor, L. S. Dissolution and Precipitation Behavior of Amorphous Solid Dispersions J. Pharm. Sci. 2011, 100 (8) 3316-3331
10. Qian, F.; Wang, J.; Hartly, R.; Tao, J.; Haddadin, R.; Mathias, N.; Hussain, M. Solution Behavior of PVP-VA and HPMC-AS-Based Amorphous Solid Dispersions and Their Bioavailability Implications Pharm. Res. 2012, 29, 2766-2776
11. Ilevbare, G. A.; Liu, H.; Pereira, J.; Edgar, K. J.; Taylor, L. S. Influence of Additives on the Properties of Nanodroplets Formed in HIghly Supersaturated Aqueous Solutions of Ritonovir Mol. Pharmaceutics 2013, 10, 3392-3403
12. Aisha, A. F. A.; Ismail, Z.; Abu-slah, K. M.; Majid, A. M. S. A. Solid Dispersions of alpha-Mangostin Improve Its Aqueous Solubility Through Self-Assembly of Nanomicelles J. Pharm. Sci. 2011, 101 (2) 815-825
13. Augustijns, P.; Brewster, M. E. Supersaturating Drug Delivery Systems: Fast is Not Necessarily Good Enough J. Pharm. Sci. 2012, 101 (1) 7-9
14. Newman, A.; Knipp, G.; Zografi, G. Assessing the Performance of Amorphous Solid Dispersions J. Pharm. Sci. 2012, 101 (4) 1355-1377
15. Hoffman, J. D. Thermodynamic driving force in nucleation and growth processes J. Chem. Phys. 1958, 29, 1192-1193
16. Ilevbare, G. A.; Taylor, L. S. Liquid-Liquid Phase Spearation in Highly Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs: Implications for Solubility Enhancing Formulations Cryst. Growth Des. 2013, 13, 1497-1509
17. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-throughput assays for promiscuous inhibitors Nat. Chem. Biol. 2005, 1 (3) 146-148
18. Warren, D. B.; Benameur, H.; Porter, C. J. H.; Pouton, C. W. Using polymeric precipitation inhibitors to improve the absorption of poorly-water soluble drugs: A mechanistic basis for utility J. Drug Targeting 2010, 18 (10) 704-731
19. Derdour, L. A method to crystallize substances that oil out Chem. Eng. Res. Des. 2010, 88, 1174-1181
20. Lafferrere, L.; Hoff, C.; Veesler, S. Study of liquid-liquid demixing from drug solution J. Cryst. Growth 2004, 269, 550-557
21. Veesler, S.; Lafferrere, L.; Garcia, E.; Hoff, C. Phase Transitions in Supersaturated Drug Solutions Org. Process Res. Dev. 2003, 7, 983-989
22. Tung, H. H.; Paul, E. L.; Midler, M.; McCauley, J. A. Critical Issues in Crystallization Practice. In Crystallization of Organic Compounds: An Industrial Perspective; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009; Chapter 5.
23. Maeda, K.; Aoyama, Y.; Fukui, K.; Hirota, S. Novel Phenomenon of cystallization and emulsification of hydrophobic solute in aqueous solution J. Colloid Interface Sci. 2001, 234, 217-222
24. Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility Advantage of Amorphous Pharmaceuticals: I. A Thermodynamic Analysis J. Pharm. Sci. 2010, 99 (3) 1254-1264
25. Baird, J. A.; Eerdenburgh, B. V.; Taylor, L. S. A classification system to assess the crystallization tendency of organic molecules form undercooled melts J. Pharm. Sci. 2010, 99, 3787-3806
26. Qian, K. K.; Wuster, D. E.; Bogner, R. H. Spontaneous Crystalline-to-Amorphous Phase Transformation of Organic or Medicinal Compounds in the Presence of Porous Media, Part 3: Effect of Moisture Pharm. Res. 2012, 29, 2698-2709
27. Thomas, J. K.; Kalyanasundaram, K. Environmental Effects on Vibronic Band Intensities in Pyrene Monomer Fluorescence and Their Application in Studies of Micellar Systems J. Am. Chem. Soc. 1977, 99 (7) 2039-2044
28. Kabanov, A. V.; Nazarova, I. R.; Astafieva, I. V.; Batrakova, E. V.; Alakhov, V. Y.; Yaroslavov, A. A.; Kabanov, V. A. Micelle Formation and Solubilization of Fluorescent Probes in Poly(oxyethylene-b-oxypropylene-b- oxyethylene) Solutions Macromolecules 1995, 28, 2303-2314
29. Yekta, A.; Dunhamel, J.; Brochard, P.; Adiwidjaja, H.; Winnik, M. A. A Fluorescent Probe Study of Micelle-like Cluster Formation in Aqueous Solutions of Hydrophobicially Modified Poly(ethylene oxide) Macromolecules 1993, 26, 1829-1836
30. Galla, H.; Sackmann, E. Lateral Diffusion in the Hydrophobic Region of Membranes: Use of Pyrene Excimers as Optical Probes Biochim. Biophys. Acta 1974, 339, 103-115
31. Trusova, V.; Yudintsev, A.; Limanskaya, L.; Gorbenko, G.; Deligeorgiev, T. Europium Coordination Complexes as Potential Anticancer Drugs: Their Partitioning and Permeation Into Lipid Bilayers as Revealed by Pyrene Fluorescence Quenching J. Fluoresc. 2013, 23, 193-202
32. Haupert, D. J.; Simpson, G. J. Chirality in nonlinear optics Annu. Rev. Phys. Chem. 2009, 60, 345-365
33. Wanapun, D.; Kestur, U. S.; Kissick, D. J.; Simpson, G. J.; Taylor, L. S. Selective Detection and Quantitation of Organic Molecule Crystallization by Second Harmonic Generation Microscopy Anal. Chem. 2010, 82, 5425-5432
34. Kissick, D. J.; Wanapun, D.; Simpson, G. J. Second Order Nonlinear Optical Imaging of Chiral Crsytals (SONICC) Annu. Rev. Anal. Chem. 2011, 4, 419-437
35. Ozaki, S.; Kushida, I.; Yamashita, T.; Hasebe, T.; Shirai, O.; Kano, K. Evaluation of Drug Supersaturation by Thermodynamic and Kinetic Approaches for the Prediction of Oral Absorbability in Amorphous Pharmaceuticals J. Pharm. Sci. 2012, 101 (11) 4220-4230
36. Raina, S. A.; Zhang, G. G. Z.; Alonzo, D. E.; Wu, J.; Zhu, D.; Catron, N. D.; Gao, Y.; Taylor, L. S. Enhancements and Limits in Drug Membrane Transport Using Supersaturated Solutions of Poorly Water-Soluble Drugs J. Pharm. Sci. 2013, 10.1002/jps.23826
37. Eerdenbrugh, B. V.; Alonzo, D. E.; Taylor, L. S. Influence of Particle Size on Ultraviolet Spectrum of Particulate-Containing Solutions: Implications for In-Situ Concentration Monitoring Using UV/Vis Fiber-Optic Probes Pharm. Res. 2011, 28, 1643-1652
38. Hiemenz, P. C.; Rajagopalan, R. Principles of Colloid and Surface Chemistry; Marcel Dekker: New York, 1997.
39. Wang, J.; Somasundaran, P. Mechanisms of ethyl(hydroxyethyl) cellulose-solid interaction: Influence of hydrophobic modification J. Colloid Interface Sci. 2006, 293 (2) 322-332
40. Rodriguez-Hornedo, N.; Murphy, D. Surfactant-Facilitated Crystallization of Dihyrdate Carbamazepine during Dissolution of Anhydrous Polymorph J. Pharm. Sci. 2004, 93 (2) 449-460
41. Yalkowsky, S. H. Solubility and solubilization in aqueous media; Oxford University Press: Washington, DC, 1999.
42. Hsieh, Y.-L.; Ilevbare, G. A.; Van Eerdenbrugh, B.; Box, K. J.; Sanchez-Felix, M. V.; Taylor, L. S. pH-Induced Precipiation Behavior of Weakly Basic Compounds: Determination of Extent and Duration of Supersaturation Using Potentiometric Titration and Correlation to Solid-State Properties Pharm. Res. 2012, 29 (10) 2738-2753
43. Anby, M. U.; Williams, H. D.; McIntosh, M.; Benameur, H.; Edwards, G. A.; Pouton, C. W.; Porter, C. J. H. Lipid Digestion as a Trigger for Supersaturation: Evaluation of the Impact of Supersaturation Stabilization on the in Vitro and in Vivo Performace of Self-Emulsifying Drug Delivery Systems Mol. Pharmaceutics 2012, 9, 2063-2079
44. Davis, A. F.; Hadgraft, J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate Int. J. Pharm. 1991, 76 (1-2) 1-8
45. Pellett, M. A.; Davis, A. F.; Hadgraft, J. Effect of supersaturation on membrane transport: 2. Piroxicam Int. J. Pharm. 1994, 111, 1-6
46. Kwong, A. D.; Kauffman, R. S.; Hurter, P.; Mueller, P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitus C virus Nat. Biotechnol. 2011, 29 (11) 993-1003
47. Shah, N.; Malick, W. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersions prepared by a solvent-controlled coprecipiation process J. Pharm. Sci. 2013, 102 (3) 967-981
48. Brouwers, J.; Brewster, M. E.; Augustijns, P. Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability J. Pharm. Sci. 2009, 98 (8) 2549-2572
49. Law, S.; Schmitt, E. A.; Marsh, K. C.; Everitt, E. A.; Wang, W.; Fort, J. J.; Krill, S. L.; Qiu, Y. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations J. Pharm. Sci. 2004, 93 (3) 563-570
50. Frank, K. J.; Westedt, U.; Rosenblatt, K. M.; Holig, P.; Rosenberg, J.; Magerlein, M.; Fricker, G.; Brandl, M. The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility Int. J. Nanomed. 2012, 7, 5757-5768
51. Mullins, J. W. Crystallization; Butterworth-Heinemann: Boston, 2001.
52. Kestur, U. S.; Wanapun, D.; Toth, S. J.; Wegiel, L. A.; Simpson, G. J.; Taylor, L. S. Nonlinear Optical Imaging for Sensitive Detection of Crystals in Bulk Amorphous Powders J. Pharm. Sci. 2012, 101 (11) 4201-4213